Cassava sciences announces expansion of open-label extension trials

Austin, texas, july 30, 2024 (globe newswire) -- cassava sciences, inc. (nasdaq: sava) today announced that the company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing phase 2 and phase 3 clinical programs. these amendments to the protocols will allow patients who have previously participated in a randomized trial of simufilam in alzheimer's disease, if they desire, to continue open-label treatment with simufilam. this expansion of the open-label extension trials offers a bridge for any gap between patients ending treatment in a clinical trial and the company reporting to regulatory authorities the results of the ongoing, randomized, placebo-controlled phase 3 trials. the open-label extension can continue for up to 36 months or until a new drug application for simufilam has been reviewed by fda.
SAVA Ratings Summary
SAVA Quant Ranking